Home

LLY

Eli Lilly and Company

NYSEHealthcareDrug Manufacturers - General

$948.45

-2.72%

2026-05-08

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Key Fundamentals

P/E Ratio

34.52

Forward P/E

22.09

EPS (TTM)

$28.18

ROE

107.5%

Revenue Growth (YoY)

55.5%

Profit Margin

35.0%

Debt/Equity

139.01

Dividend Yield

0.7%

Price/Book

27.86

Beta

0.48

Market Cap

$867.49B

Avg Volume (10D)

4.0M

Recent Breakout Signals

Near-Breakout WatchD1
2026-02-10
Near-Breakout WatchD1
2025-12-09
Momentum BreakoutD1
2025-11-10
Ceiling BreakoutD1
2025-11-10
Near-Breakout WatchD1
2025-11-06
Near-Breakout WatchD1
2024-10-15
Momentum BreakoutD1
2024-10-11
Near-Breakout WatchD1
2024-09-27
Momentum BreakoutD1
2024-08-06
Near-Breakout WatchD1
2024-07-30

Recent Price Range (60 Days)

60D High

$1067.00

60D Low

$850.51

Avg Volume

2.8M

Latest Close

$948.45

Get breakout alerts for LLY

Sign up for Breakout Scanner to receive daily notifications when LLY triggers breakout signals. Build custom AI screeners and backtest strategies.

Start Free Trial

7-day free trial. No card required.

Eli Lilly and Company (LLY) is listed on the New York Stock Exchange (NYSE). Breakout Scanner monitors LLY daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. LLY operates in the Healthcare sector within the Drug Manufacturers - General industry. Data is provided for informational purposes only and does not constitute financial advice.